BusinessInsider reports that GlaxoSmithKline pled guilty today to marketing its prescription antidepressants for uses never approved by federal regulators.
As part of a plea agreement, Glaxo will pay $3 billion to
settle a seven-year investigation into its drug marketing, Bloomberg reported
Monday.
Glaxo fessed up to illicitly promoting its antidepressant
Paxil for teens and children, and to advertising its depression drug Wellbutrin
for weight loss.
No comments:
Post a Comment